Evidence map›Paper›PMID 28074906›Full record

ArticleScientific reports2017

Antiproliferative Effects of 1α-OH-vitD

Lucia Spath, Alessandra Ulivieri, Luca Lavra, Laura Fidanza, Marta Carlesimo, Maria Giubettini, Alessandra Narcisi, Emidio Luciani, Barbara Bucci, Daniela Pisani and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Review
  5. Review
  6. Policing Cancer: Vitamin D Arrests the Cell Cycle.International journal of molecular sciences · 2020
    Review
  7. Article
  8. Review
  9. Vitamin DFrontiers in endocrinology · 2018
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Lucia SpathPathology Research Laboratory, Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Alessandra UlivieriPathology Research Laboratory, Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Luca LavraPathology Research Laboratory, Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Laura FidanzaDermatology Unit, Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Marta CarlesimoDermatology Unit, Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Maria GiubettiniPathology Research Laboratory, Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Alessandra NarcisiDermatology Unit, Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Emidio LucianiPathology Research Laboratory, Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Barbara BucciPathology Research Laboratory, Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Daniela PisaniInternal Medicine Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Salvatore SciacchitanoLaboratory of Biomedical Research, Niccolò Cusano University Foundation, via Don Carlo Gnocchi 3, 00166 Rome, Italy.
Armando BartolazziPathology Research Laboratory, Sant'Andrea University Hospital, via di Grottarossa 1035, 00189 Rome, Italy.
Azienda Ospedaliera Sant'Andrea · ITUniversity Niccolò Cusano · ITKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early detection and surgery represent the mainstay of treatment for superficial melanoma, but for high risk lesions (Breslow's thickness >0.75 mm) an effective adjuvant therapy is lacking. Vitamin D insufficiency plays a relevant role in cancer biology. The biological effects of 1α hydroxycholecalciferol on experimental melanoma models were investigated. 105 melanoma patients were checked for 25-hydroxycholecalciferol (circulating vitamin D) serum levels. Human derived melanoma cell lines and in vivo xenografts were used for studying 1α-hydroxycholecalciferol-mediated biological effects on cell proliferation and tumor growth. 99 out of 105 (94%) melanoma patients had insufficient 25-hydroxycholecalciferol serum levels. Interestingly among the six with vitamin D in the normal range, five had a diagnosis of in situ/microinvasive melanoma. Treatment with 1α-hydroxycholecalciferol induced antiproliferative effects on melanoma cells in vitro and in vivo, modulating the expression of cell cycle key regulatory molecules. Cell cycle arrest in G1 or G2 phase was invariably observed in vitamin D treated melanoma cells. The antiproliferative activity induced by 1α-hydroxycholecalciferol in experimental melanoma models, together with the discovery of insufficient 25-hydroxycholecalciferol serum levels in melanoma patients, provide the rationale for using vitamin D in melanoma adjuvant therapy, alone or in association with other therapeutic options.

Indexed as

AdultAgedAged, 80 and overCarcinogenesisCell CycleCell DifferentiationCell Line, TumorCell ProliferationCell ShapeErgocalciferolsFemaleHumansHydroxycholecalciferolsMaleMelanomaMiddle AgedalfacalcidolErgocalciferolsHydroxycholecalciferolsparicalcitol

Identifiers

PMID28074906
PMCPMC5225467
OpenAlexW2574007327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.